Trial Profile
Phase II clinical study of adapinib mesylate combined with chemotherapy in the adjuvant treatment of lung cancer after R0 resection
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2018 New trial record